Replimune Group (NASDAQ:REPL) Trading Down 7.6% – Time to Sell?

Replimune Group, Inc. (NASDAQ:REPL) shares were down 7.6% during mid-day trading on Monday . The stock traded as low as $9.63 and last traded at $9.60. Approximately 342,987 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 712,642 shares. The stock had previously closed at $10.39.

Analyst Ratings Changes

A number of equities research analysts have recently commented on REPL shares. Jefferies Financial Group increased their price target on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, December 4th. BMO Capital Markets lifted their target price on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. HC Wainwright increased their price objective on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. lifted their price objective on Replimune Group from $16.00 to $18.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Replimune Group presently has a consensus rating of “Buy” and a consensus target price of $19.43.

Replimune Group Trading Up 2.6 %

The company has a market capitalization of $663.87 million, a P/E ratio of -2.81 and a beta of 1.30. The stock has a 50 day moving average of $12.60 and a 200-day moving average of $12.14. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.09). On average, research analysts predict that Replimune Group, Inc. will post -2.97 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in REPL. Charles Schwab Investment Management Inc. boosted its holdings in shares of Replimune Group by 12.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 484,797 shares of the company’s stock worth $5,313,000 after purchasing an additional 52,498 shares during the period. Geode Capital Management LLC increased its position in Replimune Group by 17.9% during the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after acquiring an additional 217,308 shares during the last quarter. Barclays PLC lifted its holdings in shares of Replimune Group by 165.5% in the 3rd quarter. Barclays PLC now owns 158,491 shares of the company’s stock worth $1,738,000 after acquiring an additional 98,791 shares during the last quarter. Victory Capital Management Inc. bought a new position in Replimune Group during the 4th quarter valued at about $543,000. Finally, State Street Corp grew its holdings in Replimune Group by 102.1% during the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after purchasing an additional 1,182,181 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.